Global Epoetin Alfa Erythropoietin Market Size, Share and Trends Analysis Report, By Disease Indication (Anemia, Kidney Disorders, Others), By Application (Hospital, Clinic), Forecast (2022-2028)

The global epoetin alfa erythropoietin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Epoetin-alpha is a reused form of human erythropoietin. It is originally developed as an intravenous drug for the treatment of anemia in patients with chronic kidney disease and cancer with chemotherapy or radiotherapy. The increase in anemic conditions caused by end-stage renal disease, chemotherapy, and antiretroviral therapy is a major factor contributing to the growth of the erythropoietin market.

The increase in the number of chemotherapy treatments and an increase in the incidence of kidney disease increased the need for EPO. Adverse effects associated with EPO including arterial hypertension, iron deficiency, and fever-like illness and duration of EPO treatment (4-6 weeks) inhibit the growth of the erythropoietin drug market. In addition, the increase in sales of erythropoietin biosimilars, easy reimbursement, favorable government regulations, and increased awareness of the benefits of EPO Therapeutics amplify the growth of the erythropoietin drug market.

The increasing prevalence of cancer, ESRD (End-Stage Renal Disease), and HIV have contributed significantly to the increasing demand for EPO medications. About 20.0% of cancer / HIV patients and about 70.0% of ESRD patients receive chemotherapy, which often results in anemia among such patients, thus requiring appropriate EPO treatment. This is an important factor in making revenue in the erythropoietin market.

Some major players in the market include Amgen Inc., Celltrion Inc., Johnson & Johnson. Ranbaxy Laboratories Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in 2020, Akebia Therapeutics announced a collaboration with Tobacco Inc. to treat older patients with iron deficiency anemia.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease Indication
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Amgen Inc., Celltrion Inc., Johnson & Johnson. Ranbaxy Laboratories Ltd., and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Epoetin Alfa Erythropoietin Market Report by Segment

• By Disease Indication Anemia
• Kidney Disorders
• Others

By Application

• Hospital
• Clinic

Global Epoetin Alfa Erythropoietin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa